• Price (EUR)234.00
  • Today's Change6.00 / 2.63%
  • Shares traded0.00
  • 1 Year change+14.71%
  • Beta--
Data delayed at least 15 minutes, as of Aug 11 2022 07:02 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

ICON Public Limited Company is a clinical research organisation (CRO). The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. The Company specialises in the strategic development, management and analysis of programs that support clinical development from compound selection to Phase I-IV clinical studies. Its services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. It conducts various laboratory tests on the patient's blood, urine and other bodily fluids at appropriate intervals during the trial. The Company offers clinical development services, including investigator recruitment, patient registries, outcomes research, clinical data management, immunoassay development and others.

  • Revenue in USD (TTM)7.59bn
  • Net income in USD209.90m
  • Incorporated1989
  • Employees39.30k
  • Location
    ICON PLCSouth County Business Park, Dublin 18DUBLIN 00000IrelandIRL
  • Phone+353 12912000
  • Fax+353 12912700
  • Websitehttps://www.iconplc.com/
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.